Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature

Siegel, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 Ficarra, 2010, Prognostic factors in penile cancer, Urology, 76, S66, 10.1016/j.urology.2010.04.008 Clark, 2013, Penile cancer: Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 11, 594, 10.6004/jnccn.2013.0075 Hakenberg, 2015, EAU guidelines on penile cancer: 2014 update, Eur Urol, 67, 142, 10.1016/j.eururo.2014.10.017 Chipollini J, Chaing S, Azizi M, et al. Advances in understanding of penile carcinogenesis: the search for actionable targets. Int J Mol Sci 18, 2017. Garcia, 2008, Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies, Mol Cancer Ther, 7, 1347, 10.1158/1535-7163.MCT-07-2408 Rodney, 2015, Molecular markers in penile cancer, Curr Probl Cancer, 39, 137, 10.1016/j.currproblcancer.2015.03.005 Porta, 2014, Targeting PI3K/Akt/mTOR signaling in cancer, Front Oncol, 4, 64, 10.3389/fonc.2014.00064 Andersson, 2008, PIK3CA, HRAS and KRAS gene mutations in human penile cancer, J Urol, 179, 2030 Andrikopoulou, 2015, The role of mTOR signaling pathway in premalignant and malignant cervical lesions, Eur J Gynaecol Oncol, 36, 36 Ferrandiz-Pulido, 2013, mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior, J Urol, 190, 2288 Chaux, 2014, Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases, Histopathology, 64, 863, 10.1111/his.12338 Faraj, 2015, Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases, Hum Pathol, 46, 761, 10.1016/j.humpath.2015.01.018 Stankiewicz, 2011, Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas, PLoS One, 6, e17517, 10.1371/journal.pone.0017517 Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, 17, 1471, 10.1245/s10434-010-0985-4 Zargar-Shoshtari, 2016, Clinical significance of p53 and p16(ink4a) status in a contemporary North American penile carcinoma cohort, Clin Genitourin Cancer, 14, 346, 10.1016/j.clgc.2015.12.019 Nuovo, 1990, Detection of human papillomavirus DNA in penile lesions histologically negative for condylomata. Analysis by in situ hybridization and the polymerase chain reaction, Am J Surg Pathol, 14, 829, 10.1097/00000478-199009000-00004 Detre, 1995, A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas, J Clin Pathol, 48, 876, 10.1136/jcp.48.9.876 Aickin, 1996, Adjusting for multiple testing when reporting research results: the Bonferroni vs. Holm methods, Am J Public Health, 86, 726, 10.2105/AJPH.86.5.726 Li, 2016, Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis, BMC Cancer, 16, 877, 10.1186/s12885-016-2940-7 Marques, 2016, mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis, J Oral Pathol Med, 45, 319, 10.1111/jop.12390 Garcia-Carracedo, 2016, Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas, Oncotarget, 7, 29780, 10.18632/oncotarget.8957 Bahrami, 2017, The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy, J Cell Biochem, 118, 4163, 10.1002/jcb.26118 Assad, 2016, Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: a systematic review, Oncol Lett, 12, 4107, 10.3892/ol.2016.5157 Molinolo, 2012, mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas, Clin Cancer Res, 18, 2558, 10.1158/1078-0432.CCR-11-2824 Backes, 2009, Systematic review of human papillomavirus prevalence in invasive penile cancer, Cancer Causes Control, 20, 449, 10.1007/s10552-008-9276-9 Lont, 2006, Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival, Int J Cancer, 119, 1078, 10.1002/ijc.21961